Sep. 12 at 12:03 AM
$CRDF more ftom gemini
Price Targets by Scenario
* Scenario 1: Quick Settlement, No Word on Phase 3 Funding
* Expected Price Range:
$2.00 –
$4.50
* The Dynamic: Clearing the Nerviano legal cloud eliminates existential bankruptcy/IP loss fears, serving as an immediate relief catalyst that pushes the stock toward Wall Street’s median consensus targets (around
$4.50). However, because the company still faces a severe cash burn to fund Phase 3 trials on its own, a secondary stock offering or dilutive financing will loom.
* Scenario 2: Settlement + Partnership or Non-Dilutive Phase 3 Funding
* Expected Price Range:
$6.00 –
$12.00+
* The Dynamic: This matches the upper bounds of institutional analyst targets. A legal resolution combined with external capital or a pharma partnership completely shifts the fundamental thesis: the pipeline is de-risked, commercial validation is established, and equity dilution is avoided.
Contd..
